Due to scheduled maintenance, the clinical trials search and listings may be intermittently unavailable on the evening of Tuesday, 9/27/2016, from7 pm-12 am.
We apologize for the inconvenience. If you have any clinical trials questions during that period, please call 888-FOX-CHASE.
J. Robert Beck, MD
Senior Vice President
Chief Academic Officer
Chief Administrative Officer
J. Robert Beck received his AB from Dartmouth in 1974 and his MD from Johns Hopkins 1978, where he began developing his interests in health services research and health informatics. He trained in pathology and laboratory medicine at the Dartmouth-Hitchcock Medical Center, followed by a fellowship in Clinical Decision Making at the New England Medical Center. During his fellowship Dr. Beck worked with Stephen Pauker and Jerome Kassirer, and developed Markov and life expectancy models for medical decision making that have strongly influenced the field.
Bob returned to Dartmouth Medical School in 1982 as Assistant Professor of Pathology. Over the next eight years he served as medical director of the blood bank, staff hematopathologist, acting director of clinical pathology, and founding director of a program in medical information science. He was promoted to Associate Professor of Pathology and Community & Family Medicine during this period. In 1989 Dr. Beck was recruited to Oregon Health Sciences University as Professor of Pathology, Medicine, and Preventive Medicine & Public Health, where he built and directed the Biomedical Information Communication Center. He also served as OHSU’s Chief Information Officer.
In 1992 Bob moved to Baylor College of Medicine as Vice President for Information Technology and Professor of Pathology and of Community & Family Medicine. During that period he led Baylor’s NLM-funded Integrated Academic Information Management Systems initiative, developed collaborative training programs with Rice University and the University of Houston, and served on the board of the Houston Academy of Medicine – Texas Medical Center Library. He assisted the University of Texas Health Science Center at Houston in converting its School of Allied Health to one of Health Information Sciences. In 1999 Dr. Beck was asked to take an interim role as Executive Director of the HAM-TMC Library, while retaining a vice presidency for Information Research and Planning at Baylor.
Dr. Beck was recruited to Fox Chase Cancer Center in 2001 as Vice President and Chief Information Officer. He has served in several roles at Fox Chase, becoming Deputy Director of the Division of Population Sciences in 2006, Senior Vice President and Chief Academic Officer in 2007, Chief Medical Officer in 2009, and Deputy Director of the Center in 2013. In his current role Bob supervises the Office of Academic Programs, the Office of Corporate Partnerships, the Office of Health Communications and Health Disparities, the Institutional Review Board, Clinical Research Operations, Informatics, and Information Technology. He is a key advisor to the President and CEO on matters related to value creation, patient safety, investment in quality, risk management, regulatory and accreditation matters, clinical outcomes, employee and faculty engagement, medical staff and faculty governance, and public reporting. Bob serves as the Dean of the Faculty—Fox Chase has its own Appointments and Promotions structure that reports to his office. He also has a Provost function in that all academic support activities are in his purview.
Dr. Beck has published over 200 papers, has held grants throughout his career, and has served in many editorial capacities. Bob has served on non-profit, private and public corporate boards. He is a member of several academic societies, including the American College of Medical Informatics, the Society for Medical Decision Making (for which he served as President), and the College of American Pathologists.
I serve as Deputy Director as well as Chief Academic and Administrative Officer for Fox Chase Cancer Center (FCCC). My role is akin to Provost or Academic Affairs Dean in a typical university setting. I supervise the activities of the Institutional Review Board, the current Chief Information Officer, the Facility Director of the Biostatistics and Bioinformatics Facility (BBF), and the Population Studies Facility (PSF). I mentor trainees and junior faculty, and support health services research with methodological work in decision science.
Upon joining Steve Pauker’s group in clinical decision making as a Fellow in 1981, we developed alternatives to the static utility formalism of decision trees. My first clinical decision consult established the paradigm of Markov state transition modeling of clinical outcomes, and I proceeded to develop the methodology and tutorials. The early Markov papers have been cited themselves over 1700 times, and the techniques are now part of standard texts and references in medical decision making. A PubMed search: Markov and (Decision or Cost-effectiveness) returns over 4500 papers.
Accompanying the Markov modeling work, we have pioneered new outcome measures for medical decision making. Clinical decision models of chronic diseases required a method of representing outcomes as life expectancies, modified by competing risks of mortality. We developed a convenient approximation of life expectancy that, before the advent of powerful computers, enabled useful and relatively accurate decision modeling. The Declining Exponential Approximation of Life Expectancy is still cited (over 600 total) and being improved.
As a clinical pathologist, our group blended applied mathematics and decision science training to advance applications of these technologies to laboratory diagnosis. Important papers in this arena included articles on ROC analysis and likelihood ratios, applied to clinical laboratory tests. As an academic chief information officer, my groups made contributions to a number of areas in medical informatics, including shared decision making, workstation development, biomedical informatics communities, and artificial intelligence. Projects with trainees have emphasized cost-effectiveness of cancer therapies and diagnostic procedures, especially when there are methodologic nuances.
Nghiem V, Davies K, Beck JR, Follen M, MacAulay C, Guillaud M, Cantor S. Economic evaluation of DNA ploidy analysis versus liquid-based cytology for cervical screening. British Journal of Cancer 112:1951-1957, 2015.
Wong YN, Egleston BL, Sachdeva KS, Eghan N, Pirollo M, Stump TK, Beck JR, Armstrong K, Schwartz JS, Meropol NJ. Cancer patients' trade-offs among efficacy, toxicity and out-of-pocket cost in the curative and non-curative setting. Medical Care 51:838-845, 2013.
Min H, Manion FJ, Goralczyk E, Wong Y-N, Ross E, Beck JR. Integration of prostate cancer clinical data using an ontology. Journal of Biomedical Informatics 42:1035-1045, 2009. [PMCID: PMC2784120]
Wong Y-N, Meropol NJ, Speier WF, Sargent D, Goldberg R, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer 115:2081-2091, 2009. [PMCID: PMC2875773]
Konski A, Hanlon A, Beck JR, Pollack A. Is proton beam therapy cost-effective in the treatment of adenocarcinoma of the prostate? Journal of Clinical Oncology 25:3603-3608, 2007.
Zupan B, Demsar J, Kattan MW, Beck JR, Bratko I. Machine learning for survival analysis: A case study on recurrence of prostate cancer. Artificial Intelligence in Medicine, 20:59-76, 2000.
Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C. Annals of Internal Medicine 127:855-865, 1997.
Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR. Cost-effectiveness of alpha-interferon compared to conventional chemotherapy in chronic myelogenous leukemia. Annals of Internal Medicine 125:541-548, 1996.
Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Medical Decision Making 13:322-338, 1993.
Helfand M, O’Connor GT, Zimmer-Gembeck M, Beck JR: Effect of the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88) on the incidence of invasive cervical cancer. Medical Care 30:1067-1082, 1992.
Beck JR, Shultz EK: The use of relative operating characteristic (ROC) curves in test performance evaluation. Archives of Pathology and Laboratory Medicine 110:13-20, 1986.
Beck JR, Pauker SG: The Markov process in medical prognosis. Medical Decision Making 3:419-458, 1983.
Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP: A convenient approximation of life expectancy (the "DEALE"): II. Use in medical decision making. American Journal of Medicine 73:889-897. 1982.
Beck JR, Kassirer JP, Pauker SG: A convenient approximation of life expectancy (the "DEALE"): I. Validation of the method. American Journal of Medicine 73:883-888, 1982.
Beck JR, Pauker SG: Anticoagulation and atrial fibrillation in the bradycardia-tachycardia syndrome. Medical Decision Making 1(3):285-301, 1981.